Tags

Type your tag names separated by a space and hit enter

Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation.
Cytotherapy. 2017 02; 19(2):194-199.C

Abstract

BACKGROUND AIMS

Ischemic-type biliary lesions are severe, graft-threatening complications after orthotopic liver transplantation, and a novel and efficient therapeutic strategy is urgently needed. Due to the immunosuppressive and regenerative properties, mesenchymal stromal cells (MSCs) could be an interesting candidate.

METHODS

We initiated safety and efficacy of human umbilical cord-derived MSC (UC-MSC) transfusions for patients with ischemic-type biliary lesions after liver transplantation. From January 2013 to June 2014, 12 ischemic-type biliary lesions patients were recruited as the MSCs group in this phase I, prospective, single-center clinical study. Patients in this group received six doses of UC-MSCs (about 1.0 × 106 MSCs per kilogram body weight through peripheral intravenous infusion). The traditional therapeutic protocol was applied during October 2003 to December 2012 in 70 ischemic-type biliary lesions patients who were treated as the control group. Liver function tests, the need for interventional therapies and graft survival rate were chosen to evaluate the therapeutic efficacy of MSC treatment. Adverse events were closely monitored up to 2 years after MSC transfusions.

RESULTS

No significant MSC-related adverse events were observed during the trial. Compared with baseline, the levels of total bilirubin, γ-glutamyl transferase and alkaline phosphatase were decreased after UC-MSC treatment at week 20 and week 48. Interventional therapies were performed in 64.3% (45/70) of patients in the control group and 33.3% (4/12) of patients in the MSCs groups. MSC therapy significantly decreased the need for interventional therapies (P = 0.046). The 1- and 2-year graft survival rates were higher in the MSCs group (100% and 83.3%, respectively) than in the control group (72.9% and 68.6%, respectively).

CONCLUSIONS

The UC-MSC transfusions are clinically safe and short-term favorable, which may become a novel treatment for patients with ischemic-type biliary lesions after liver transplantation.

Authors+Show Affiliations

Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Cell-Gene Therapy Translational Medicine Research Center, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Guangdong Province Key Laboratory of Hepatology Research, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Surgery Intensive Care Unit, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.Cell-Gene Therapy Translational Medicine Research Center, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China; Guangdong Province Key Laboratory of Hepatology Research, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: keekee77@126.com.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Electronic address: yysysu@163.com.Department of Liver Surgery and Liver Transplantation, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Pub Type(s)

Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

27964826

Citation

Zhang, Ying-Cai, et al. "Therapeutic Potentials of Umbilical Cord-derived Mesenchymal Stromal Cells for Ischemic-type Biliary Lesions Following Liver Transplantation." Cytotherapy, vol. 19, no. 2, 2017, pp. 194-199.
Zhang YC, Liu W, Fu BS, et al. Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. Cytotherapy. 2017;19(2):194-199.
Zhang, Y. C., Liu, W., Fu, B. S., Wang, G. Y., Li, H. B., Yi, H. M., Jiang, N., Wang, G., Zhang, J., Yi, S. H., Li, H., Zhang, Q., Yang, Y., & Chen, G. H. (2017). Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. Cytotherapy, 19(2), 194-199. https://doi.org/10.1016/j.jcyt.2016.11.005
Zhang YC, et al. Therapeutic Potentials of Umbilical Cord-derived Mesenchymal Stromal Cells for Ischemic-type Biliary Lesions Following Liver Transplantation. Cytotherapy. 2017;19(2):194-199. PubMed PMID: 27964826.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic potentials of umbilical cord-derived mesenchymal stromal cells for ischemic-type biliary lesions following liver transplantation. AU - Zhang,Ying-Cai, AU - Liu,Wei, AU - Fu,Bin-Sheng, AU - Wang,Guo-Ying, AU - Li,Hai-Bo, AU - Yi,Hui-Min, AU - Jiang,Nan, AU - Wang,Genshu, AU - Zhang,Jian, AU - Yi,Shu-Hong, AU - Li,Hua, AU - Zhang,Qi, AU - Yang,Yang, AU - Chen,Gui-Hua, Y1 - 2016/12/08/ PY - 2016/07/24/received PY - 2016/11/07/revised PY - 2016/11/09/accepted PY - 2016/12/15/pubmed PY - 2017/8/3/medline PY - 2016/12/15/entrez KW - ischemic-type biliary lesions KW - liver transplantation KW - mesenchymal stromal cells KW - umbilical cord SP - 194 EP - 199 JF - Cytotherapy JO - Cytotherapy VL - 19 IS - 2 N2 - BACKGROUND AIMS: Ischemic-type biliary lesions are severe, graft-threatening complications after orthotopic liver transplantation, and a novel and efficient therapeutic strategy is urgently needed. Due to the immunosuppressive and regenerative properties, mesenchymal stromal cells (MSCs) could be an interesting candidate. METHODS: We initiated safety and efficacy of human umbilical cord-derived MSC (UC-MSC) transfusions for patients with ischemic-type biliary lesions after liver transplantation. From January 2013 to June 2014, 12 ischemic-type biliary lesions patients were recruited as the MSCs group in this phase I, prospective, single-center clinical study. Patients in this group received six doses of UC-MSCs (about 1.0 × 106 MSCs per kilogram body weight through peripheral intravenous infusion). The traditional therapeutic protocol was applied during October 2003 to December 2012 in 70 ischemic-type biliary lesions patients who were treated as the control group. Liver function tests, the need for interventional therapies and graft survival rate were chosen to evaluate the therapeutic efficacy of MSC treatment. Adverse events were closely monitored up to 2 years after MSC transfusions. RESULTS: No significant MSC-related adverse events were observed during the trial. Compared with baseline, the levels of total bilirubin, γ-glutamyl transferase and alkaline phosphatase were decreased after UC-MSC treatment at week 20 and week 48. Interventional therapies were performed in 64.3% (45/70) of patients in the control group and 33.3% (4/12) of patients in the MSCs groups. MSC therapy significantly decreased the need for interventional therapies (P = 0.046). The 1- and 2-year graft survival rates were higher in the MSCs group (100% and 83.3%, respectively) than in the control group (72.9% and 68.6%, respectively). CONCLUSIONS: The UC-MSC transfusions are clinically safe and short-term favorable, which may become a novel treatment for patients with ischemic-type biliary lesions after liver transplantation. SN - 1477-2566 UR - https://www.unboundmedicine.com/medline/citation/27964826/Therapeutic_potentials_of_umbilical_cord_derived_mesenchymal_stromal_cells_for_ischemic_type_biliary_lesions_following_liver_transplantation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1465-3249(16)30584-9 DB - PRIME DP - Unbound Medicine ER -